Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-08-22 10:18Core Viewpoint - Shenzhen Chipscreen Biosciences Co., Ltd. is preparing for a specific issuance of A-shares in 2024, with Guotou Securities acting as the sponsor, ensuring compliance with relevant laws and regulations [1][2]. Group 1: Issuance Details - Guotou Securities has been appointed as the sponsor for the issuance of A-shares for Shenzhen Chipscreen in 2024, with representatives Hu Jiabin and Song Qian responsible for the due diligence and ongoing supervision [2][3]. - The issuance will involve a maximum of 58,125,305 shares, not exceeding 30% of the total share capital prior to the issuance [23][24]. Group 2: Company Overview - Shenzhen Chipscreen was established on March 21, 2001, with a registered capital of 408.54 million yuan and is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board [5]. - The company focuses on drug technology development, new drug research, and related services, with a commitment to innovation in the biopharmaceutical sector [5]. Group 3: Financial Performance - As of March 31, 2025, the total assets of the company amounted to 331,170.31 million yuan, with total liabilities of 174,984.07 million yuan [8]. - The company reported a total revenue of 16,226.37 million yuan for the first quarter of 2025, with a net loss attributable to shareholders of 1,915.47 million yuan [8]. Group 4: Shareholder Structure - As of March 31, 2025, the top ten shareholders collectively hold 41.48% of the company's shares, with significant stakes held by various investment partnerships [5][11]. - The actual controller, Xianping Lu, holds 5.45% of the shares directly and controls a total of 22.00% through various partnerships [11][12]. Group 5: Future Plans and Use of Proceeds - The funds raised from the issuance will be allocated to innovative drug research and development projects, including the establishment of a new drug manufacturing base [23][24]. - The company has not distributed profits from 2022 to 2024, focusing on reinvestment for growth and development [6].